06/29/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/29/2020. This web page provides information about the emergency use authorizations (EUAs) issued by the Food and Drug Administration to help increase the availability of ventilators and ventilator accessories, which are integral to treat patients with severe respiratory distress during the COVID-19 pandemic. (Text)
06/26/2020 12:00 AM EDT
Source: U.S. Food and Drug Administration (FDA). Published: 6/26/2020. This seven-page letter details the Emergency Use Authorization (EUA) for the Inform Diagnostics SARS-CoV-2 RT-PCR Assay for qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal, oropharyngeal, anterior nasal, and mid-turbinate nasal swabs, as well as nasopharyngeal wash/aspirate or nasal aspirates, and bronchoalveolar lavage (BAL) specimens from individuals suspected of COVID-19 by their healthcare provider. (PDF)
06/26/2020 12:00 AM EDT
Source: National Emerging Special Pathogens Training and Education Center (NETEC). Published: 6/26/2020. This 55-minute webinar features speakers who provide deeper insight into respiratory failure and the context of COVID-19, pathophysiology in the hypercoagulable state, and the COVID-19 “Cytokine Storm” - myth or reality. (PDF)
06/25/2020 12:00 AM EDT
Source: Center for Health Security [Johns Hopkins University, Bloomberg School of Public Health]. Published: 6/25/2020. This 16-page report summarizes a study to develop an expert assessment of the promise and challenges posed by at-home infectious diagnostic technologies. A major aim of the study is to inform pandemic preparedness activities that rely on diagnostic technologies and determine how at-home approaches can integrate with and augment the existing diagnostic paradigm. Limitations surrounding access to diagnostic testing have dominated much of the current response to COVID-19 and highlight the need to have more rapid, convenient, and equitable access to testing. (PDF)
06/24/2020 12:00 AM EDT
Source: Centers for Disease Control and Prevention (CDC). Published: 6/24/2020. This 53-minute Emergency Partners Information Connection (EPIC) webinar addresses the current status of the COVID-19 pandemic in the U.S., factors to consider when deciding to participate in activities outside of the home, and special considerations for the upcoming Fourth of July weekend. (Video or Multimedia)
06/24/2020 12:00 AM EDT
Source: National Institutes of Health (NIH). Published: 6/24/2020. Efforts to develop antiviral drugs versus COVID-19 or vaccines for its prevention have been hampered by limited knowledge of the molecular details of SARS-CoV-2, the virus that causes COVID-19. This 56-minute webinar describes Nevan Krogan's efforts to address this challenge. He and his lab expressed 26 of the 29 SARS-CoV-2 proteins in human cells and are using affinity–purification mass spectrometry to identify the human proteins physically associated with each. (Video or Multimedia)
06/01/2020 12:00 AM EDT
Source: U.S. Government Accountability Office (GAO). Published: 6/2020. This 403-page report examines key actions the federal government has taken to address the COVID-19 pandemic and evolving lessons learned relevant to the nation’s response to pandemics, among other things. It discusses sources of federal funding, including the Public Health and Social Services Emergency Fund from the Department of Health and Human Services. (PDF)
05/27/2020 12:00 AM EDT
Source: National Institutes of Health (NIH). Published: 5/27/2020. This one-hour, four-minute webinar discusses SARS-CoV-2, the newly emerged coronavirus responsible for the current COVID-19 pandemic, and the coronavirus spike (S) glycoprotein trimers that promote the virus’s entry into cells and are the main targets of the humoral immune response. (Video or Multimedia)
05/06/2020 12:00 AM EDT
Source: National Institutes of Health (NIH). Published: 5/6/2020. Although data on COVID-19 disease in humans are emerging at a steady pace, this one-hour 12-minute presentations discusses how certain aspects of the pathogenesis of SARS-CoV-2 can only be studied in detail in animal models where repeated sampling and tissue collection are possible. Non-human primate models that recapitulate aspects of human disease are essential for the understanding of the pathogenic processes involved in severe respiratory disease and for the development of medical countermeasures such as vaccines and antivirals. (Video or Multimedia)
05/01/2020 12:00 AM EDT
Source: Office of the Assistant Secretary for Preparedness and Response [U.S. Department of Health and Human Services] (HHS ASPR). Published: 5/2020. This webinar series, held with the Department of Homeland Security (DHS) and InfraGard National Capital Region (InfraGard NCR), informs the private sector, state and local government first responders, and public healthcare professionals of potential increased threats to healthcare and public health facilities during the COVID-19 pandemic. The webinars explore physical security challenges facing healthcare, medical manufacturing, and research communities due to their criticality to the COVID-19 response. (Video or Multimedia)
05/01/2020 12:00 AM EDT
Source: Reagan-Udall Foundation for the FDA. Published: 5/2020. This web page provides information about the meetings of the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder, collaborative project leveraging real-world data in the diagnostic (e.g., nucleic acid or antigenic) and antibody testing (e.g., serological) space. The goal is to present and discuss information on recent analyses of real-world data related to test performance, contemporaneous symptoms and presentation, surveillance trends, and immunity to peers and experts from the FDA, major technology companies, academic research institutions, device manufacturers, payers, and health systems. (Text)
04/01/2020 12:00 AM EDT
Source: Ohio State University (OSU). Published: 4/2020. This survey was created in April 2020, and first administered in June 2020. It is targeted to established cohorts who must be current residents of Ohio. Population: Adults Only Ethnic/Religious Groups Sexual or Gender Minorities Length: 131 questions Time to Complete: 30 minutes self-administered, 45 minutes interviewer-administered Mode of Administration: Online (e.g., computer-assisted interview) Pen and Paper Telephone Administered by: Professional Interviewer Self-Administered Language(s): English (PDF)
.png)
No hay comentarios:
Publicar un comentario